论文部分内容阅读
目的:探讨地西他滨(decitabine,DCA)和丙戊酸钠(valproic acid,VPA)联用对AML患者原始细胞体外的影响。方法:设立分组如下:对照组,DCA单药A组(1.0μmol/L),DCA单药B组(4.0μmol/L),VPA单药组(2.0 mmol/L),联合用药A组(DCA 1.0μmol/L+VPA 2.0 mmol/L),联合用药B组(DCA4.0μmol/L+VPA 2.0 mmol/L),作用48 h。应用流式细胞术检测早期凋亡率和CD117、CD14表达率。结果:相对于各自的单药组,联合用药A组和联合用药B组均能显著提高早期凋亡率和CD14表达,抑制CD117的表达(P<0.01)。结论:体外DCA联合VPA能显著加强抗白血病效应。
Objective: To investigate the effects of decitabine (DCA) and valproic acid (VPA) on the proliferation of primary AML patients in vitro. Methods: The following groups were established: control group, DCA single drug group (1.0μmol / L), DCA single drug group B (4.0μmol / L), VPA single drug group (2.0mmol / L) 1.0μmol / L + VPA 2.0 mmol / L) for 48 h in combination group B (DCA 4.0 μmol / L + VPA 2.0 mmol / L). Flow cytometry was used to detect the early apoptosis rate and CD117, CD14 expression rate. Results: Compared with their respective single drug group, the combination of drug combination group A and combination group B could significantly increase the early apoptosis rate and CD14 expression, and inhibit the expression of CD117 (P <0.01). Conclusion: In vitro DCA combined with VPA can significantly enhance the anti-leukemia effect.